samedan logo
 
 
 
spacer
home > ebr > summer 2019 > a new lens
PUBLICATIONS
European Biopharmaceutical Review

A New Lens

Precision medicine promises to deliver better medicines, improved patient outcomes, and lower healthcare costs. It has the potential to benefit millions of patients and save global healthcare systems tens or even hundreds of billions of US dollars per year through new, better targeted therapeutic options, reduced misprescription and over-medication, and better patient compliance.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Steve Gardner has over 25 years’ experience building world-class teams, products, and companies. He has raised venture funding in the UK, EU, and US to develop and market highly innovative and commercially successful products in the life sciences, healthcare, and food industries. Steve was Global Director of Research Informatics for AstraZeneca. He specialises in AI-enabled drug discovery and precision medicine, semantic data integration and complex data analytics for life sciences, healthcare, and clinical decision support. Steve is an Advisory Council member for Breast Cancer Now and is on the Steering Committee of the UKCRC Tissue Coordination Centre.
spacer
Steve Gardner
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Tempus Announces Agreement With Janssen R&D to Leverage AI/ML and Real-World Evidence to Enhance the Discovery and Development of Oncology Therapies

Tempus, a leader in artificial intelligence and precision medicine, today announced the expansion of its multi-year agreement with Janssen Research & Development, LLC (Janssen).
More info >>

White Papers

Achieve full compliance with tamper-verification pharma solutions

UPM Raflatac

UPM Raflatac has developed a range of pharmaceutical labelling products to support compliance with the Falsified Medicines Directive on packaging for prescription drugs and high-risk, over-the-counter medicines. Few solutions offer the same ease of adoption for meeting the February 2019 deadline.
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement